EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
UPS MD-11 Crash Prompts Families to Prepare Wrongful Death Lawsuit 
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup 
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum 
Visa to Move European Headquarters to London’s Canary Wharf 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
IKEA Expands U.S. Manufacturing Amid Rising Tariffs and Supply Chain Strategy Shift 
USPS Expands Electric Vehicle Fleet as Nationwide Transition Accelerates 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry 
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO 
Sam Altman Reportedly Explored Funding for Rocket Venture in Potential Challenge to SpaceX 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
BERKELEY, Calif., Dec. 02, 2015 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Gregory W. Schafer, chief operating officer of Aduro, will present at Oppenheimer’s 26th Annual Healthcare Conference in New York on Wednesday, December 9, 2015, at 9:45 am Eastern Time.
To access the live webcast and subsequent archived recording of this and the company’s other presentations, please visit Aduro's website at www.aduro.com.
About Aduro
Aduro Biotech, Inc. is a clinical-stage immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. Based on compelling clinical data in advanced cancers, this platform is being developed as a treatment for multiple indications, including pancreatic, lung and prostate cancers, mesothelioma and glioblastoma. Aduro's cyclic dinucleotide (CDN) platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.
Contact: Sylvia Wheeler SVP, Corporate Affairs 510 809 9264 Media Contact: Angela Bitting 925 202 6211 [email protected]
